Page last updated: 2024-12-05

2-methylpiperidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-methylpiperidine: RN given refers to parent cpd without isomeric designation; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7974
CHEMBL ID21454
CHEBI ID186840
MeSH IDM0134643

Synonyms (65)

Synonym
nsc31047
nsc-31047
alpha-methylpiperidine
alpha-pipecolin
einecs 203-642-1
alpha-pipecoline
brn 0079804
nsc 31047
109-05-7
pipicoline
.alpha.-methylpiperidine
nsc-462
wln: t6mtj b1
pipecoline, alpha
2-pipecoline
.alpha.-pipecoline
piperidine, 2-methyl-
2-methylpiperidine
nsc462
.alpha.-pipecolin
2-methylpiperidine, 98%
CHEMBL21454
2-methyl-piperidine
P0443
CHEBI:186840
AKOS000120096
5-20-04-00071 (beilstein handbook reference)
22e509663b ,
unii-22e509663b
FT-0613360
FT-0645283
AM20080042
AKOS016039384
(+/-)-2-methylpiperidine
dl-2-methylpiperidine
2-methylpiperidine [fhfi]
fema no. 4244
(+/-)-.alpha.-pipecoline
a-pipecoline
2-methyl piperidine
2-methylpyperidine
rac.-2-methylpiperidine
(+/-)-2-methyl-piperidine
(rs) 2-(methyl)piperidine
pipecoline, .alpha.
mfcd00005982
J-510078
F2190-0326
2-methylpiperidine, analytical standard
alpha -pipecoline
alpha -pipecolin
2-pipecoline (8ci)
alpha -methylpiperidine
d-alpha-pipecoline
FT-0773721
DTXSID90861728
STL183272
STR03043
Q27253646
F93019
SB44682
SB44667
EN300-20696
2-methyl hexahydropyridine
Z104479894
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
L-ornithine degradation II (Stickland reaction)1043
L-arginine degradation (Stickland reaction)1254

Protein Targets (11)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neuronal acetylcholine receptor subunit alpha-3Rattus norvegicus (Norway rat)Kd0.00010.00000.00010.0003AID30393
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Kd0.00010.00000.00010.0001AID30393
Neuronal acetylcholine receptor subunit alpha-2Rattus norvegicus (Norway rat)Kd0.00010.00000.00010.0001AID30393
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Kd0.00010.00000.00000.0001AID30393
Neuronal acetylcholine receptor subunit beta-3Rattus norvegicus (Norway rat)Kd0.00010.00010.00010.0001AID30393
Neuronal acetylcholine receptor subunit beta-4Rattus norvegicus (Norway rat)Kd0.00010.00010.00010.0003AID30393
Neuronal acetylcholine receptor subunit alpha-5Rattus norvegicus (Norway rat)Kd0.00010.00010.00010.0001AID30393
Neuronal acetylcholine receptor subunit alpha-6Rattus norvegicus (Norway rat)Kd0.00010.00010.00010.0001AID30393
Neuronal acetylcholine receptor subunit alpha-9Rattus norvegicus (Norway rat)Kd0.00010.00010.00010.0001AID30393
Neuronal acetylcholine receptor subunit alpha-7Rattus norvegicus (Norway rat)Kd0.00010.00010.00010.0001AID30393
Neuronal acetylcholine receptor subunit alpha-10Rattus norvegicus (Norway rat)Kd0.00010.00010.00010.0001AID30393
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneNeuronal acetylcholine receptor subunit alpha-9Rattus norvegicus (Norway rat)
plasma membraneNeuronal acetylcholine receptor subunit alpha-10Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID30377Maximum percent of enhancement of binding.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30527Compounds was evaluated for their ability to enhance (+/-)-[3H]nicotine binding at a dose range 10 E -10 - 10 E -4 M was reported; response was dose related1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30393Compounds was evaluated in vitro for ability to enhance and inhibit the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-10-10e-31985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30378Maximum percent of inhibition of binding was determined1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30389Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 21985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (55.56)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's2 (22.22)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.14 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index57.38 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]